department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Dimethyl Fumarate · pharmadog

pharmadog
drugs
Dimethyl Fumarate

drug

patient view →

dimethyl fumarate DR

Marketedupdated 2mo ago

by SOLA Pharmaceuticals Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Dimethyl Fumarate

generic

dimethyl fumarate

indication

Relapsing Multiple Sclerosis (RMS)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 7, 2028

~1.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

Nov 16, 2035method-of-use (U-1384)US 10959972
Nov 16, 2035method-of-use (U-1384)US 10959972
Nov 16, 2035method-of-use (U-1384)US 11007166
Nov 16, 2035method-of-use (U-1384)US 11007166
Nov 16, 2035method-of-use (U-1384)US 11007167
Nov 16, 2035method-of-use (U-1384)US 11007167
Nov 16, 2035method-of-use (U-1384)US 11129806
Nov 16, 2035method-of-use (U-1384)US 11129806
Nov 16, 2035method-of-use (U-1384)US 11246850
Nov 16, 2035method-of-use (U-1384)US 11246850
Mar 13, 2035method-of-use (U-3148)US 10391160
Mar 13, 2035method-of-use (U-3148)US 10391160
Mar 13, 2035method-of-use (U-3148)US 10555993
Mar 13, 2035method-of-use (U-3148)US 10555993
Mar 13, 2035method-of-use (U-3148)US 10994003
Mar 13, 2035method-of-use (U-3148)US 10994003
Feb 7, 2028method-of-use (U-1384)US 83995141.6y
Feb 7, 2028method-of-use (U-1384)US 83995141.6y

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying dimethyl fumarate DR

—A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosisrecruitingn=800
phase3A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)not yet recruitingn=185
phase3Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitusrecruitingn=90
—A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)active not recruitingn=10,500
phase4A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)not yet recruitingn=50
—Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)recruitingn=908
phase3Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)completedn=156
phase4A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in Chinacompletedn=60

more trials →